Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Septerna sells GPCR program to Vertex for $48 million

by Laurel Oldach
September 29, 2023 | A version of this story appeared in Volume 101, Issue 32

 

Septerna, a biotechnology company focused on developing new small-molecule drugs for G-protein-coupled receptors (GPCRs), has sold a GPCR program to Vertex Pharmaceuticals for $47.5 million. Vertex sells several cystic fibrosis therapies and is pursuing treatments for other diseases. The agreement, announced just 2 months after Septerna closed a $150 million round of series B funding, concerns a discovery-stage Septerna program targeting an undisclosed receptor. If the program meets preclinical milestones, Septerna stands to earn additional payouts.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.